亿帆医药最新公告：公司部分产品纳入国家医保目录

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that certain self-owned or imported products from its wholly-owned or controlled subsidiaries have been included in the National Medical Insurance Catalog for 2025, which is expected to facilitate market expansion and increase product sales, although it will not have a significant impact on the company's performance in the short term [1] Group 1 - The innovative drug Aibegesitin α injection (Yilishu), imported general agent product Dihyaluronic Acid Sodium Injection (Yinikon), and Compound Huangdai Tablets (Baixuekang) are included in the catalog [1] - The inclusion of these products in the medical insurance catalog is beneficial for market development and sales growth [1] - The impact on the company's performance will be limited in the short term [1]